期刊文献+

首发和慢性精神分裂症患者眼动改变 被引量:3

原文传递
导出
摘要 目的探讨首发和慢性精神分裂症患者的眼动改变。方法应用眼动检测仪对首发(首发组)和慢性(慢性组)精神分裂症患者分别于治疗前后进行检查,同时设正常对照组;用凝视点数(NEF)值和反应性探索评分(RSS)值作为探究性眼动观察值,并在三组间及治疗前后进行比较。结果两组治疗前NEF和RSS均显著低于正常对照组;经8周抗精神病药使用后,慢性组NEF仍低于正常对照组;首发组和慢性组的RSS评分仍低于正常对照组,差异有统计学意义(P<0.01)。结论慢性精神分裂症患者认知功能损害比首发精神分裂症患者更加明显,且更难通过治疗而得到显著改善。
出处 《江苏医药》 CAS CSCD 北大核心 2009年第12期1494-1495,共2页 Jiangsu Medical Journal
  • 相关文献

参考文献9

  • 1Leucht S, Lasser R. The concept of remission and recovery in schizophrenia[J]. Pharmacopsychiatry, 2006,39(5) : 161-170.
  • 2Lieberman RP, Kopelowicz A. Recovery from schizophrenia:a concept in search of research [J ]. Psychiatric Serv, 2005, 56 (6) :735-742.
  • 3van OS J, Burns T, Cavallaro R, et al. Standardized remission criteria in schizophrenia[J]. Acta Psychiatr Scand , 2006, 113 (2):91-95.
  • 4Thompson JL, Watson JR, Steinhauer SR, et al. Indicators of genetic liability to schizophrenia: a sibling study of neuropsychological performance[J]. Schizophr Bull, 2005,31 (1) : 85-96.
  • 5Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic sehizoaffeetive disorder[J]. Am J Psychiatry, 2002,159(6) : 1018-1028.
  • 6Keefe RS, Bilder RM, Harvey PD, et al. Baseline neurocognitive defieits in the CATIE schizophrenia trial [J]. Neuropsychopharmaclology, 2006,31 ( 9 ) : 2033-2046.
  • 7Green MF, Kern RS, Braff DL, et al. Neuroeognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"[J]? Schizophr Bull, 2000,26 ( 1 ) : 119-136.
  • 8Hofer A, Baumgartner S, Edinger M, et al. Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology,and side effects[J]. Enr Psychiatry, 2005,20 (5) :386-394.
  • 9王丽莉,韩永华,朱日升.不同病程的精神分裂症患者探究性眼动分析[J].中国心理卫生杂志,2003,17(10):702-704. 被引量:26

二级参考文献4

共引文献25

同被引文献20

  • 1项志清,陈月敏,颜文伟.探索性眼球活动试验在精神分裂症诊断中的价值[J].上海精神医学,2004,16(5):263-266. 被引量:28
  • 2寇根生,张宁,张建宏,陈佐明.精神分裂症与抑郁症患者探究性眼动与事件相关电位分析[J].中国实用医刊,2010,37(13):10-12. 被引量:2
  • 3沈渔邮,主编.精神病学[M].第五版,北京:人民卫生出版社,2010:245.
  • 4Georg J, Daniela S, Nina F, et al. Validation of the personal per- formance (PSP) scale in a german sample of acutely ill patients with schizophrenia [ J ]. Schizophrenia Research, 2008 : 287-293.
  • 5Akdede BB, Anil Yagcioglu AE, AlpttkinK etal, A double-blind study of combination of clozapine with Risperidone in patients with Schizophrenia: effection congnition [ J ]. Clin psychiatry, 2006,67 : 1912-1919.
  • 6Rosenheck RA, Ceslie PL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trail of treatment for chronic Schizophrenia [ J ], Am J psychiatry, 2006,163 : 2029-2031.
  • 7沈渔郝.精神病学[M].第5版.北京:人民卫生出版社,2009:605.
  • 8Akdede BB, Anil "Y, Alptfkin K, et al. A double -blind study of combina- tion of clozapine with Risperidone in patients with Schizophrenia : effection congnition [J]. Clin Psychiatry,2006,67 : 1 912 - 1 919.
  • 9Dremcncov E, Mansani MEI, Blier P, et al. Distinct electrophysiological ef- fects of paliperidone and rispefidone on the firing activity of rat serotonin and norepinephrine neurons [ J ]. Psyehopharmacology,2007,194 (3) : 63 - 72.
  • 10Dolder C. Review: paliperidone reduces symptoms of schizophrenia and schizophrenia - like illness[J]. Evid Based Merit Health,2008,11 (4) : 114.

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部